Topical Cyclosporine and Disease Progression

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00567983

Enrollment

Registered

2007-12-05

Start date

2007-12-31

Completion date

2008-09-30

Last updated

2008-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disease Progression, Disease Severity, Staining, Schirmers, OSDI

Brief summary

The purpose of this study is to evaluate the effect Restasis has in regards to disease progression.

Interventions

DRUGRestasis

Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily

DRUGEndura

Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Mild to Moderate dry eye symptoms

Exclusion criteria

* Current use of Restasis

Design outcomes

Primary

Measure	Time frame
Disease Severity	1 yr

Secondary

Measure	Time frame
Staining	1 yr

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026